Arcadia Biosciences Raises $4M, Existing Shareholders Face Dilution

Arcadia Biosciences raised $4 million through a private placement that will dilute existing shareholders. The wellness-products company sold roughly 3.9 million shares at $1.03 each, or pre-funded warrants in their place, and attached two sets of options that could add another 7.8 million shares to the total.

H.C. Wainwright & Co. acted as the exclusive placement agent. The deal closed June 12. After deducting placement agent fees and other expenses, the net proceeds will be less than $4 million. Arcadia said it will use the funds for working capital and general corporate purposes.

The option structure has two tranches. Series A-1 preferred investment options carry a $0.91 strike price. They become exercisable only after stockholders approve the underlying share issuance, a vote not yet scheduled. Series A-2 options also have a $0.91 strike and are exercisable immediately upon issuance, with the trigger being an effective SEC resale registration statement. Arcadia agreed to file that registration statement but has not yet done so. Neither event is guaranteed to happen quickly, if at all.

Based on the 13.9 million shares outstanding as of the company's last 10-K, the new shares alone increase the count by 28%. If both option tranches are exercised fully, the total share count could more than double from the pre-offering base. The $0.91 exercise price sits below the $1.03 placement price, so option holders are already in the money relative to the offering.